The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Trials and Tribulations of CETP Inhibitors
Open accessAbstract
The development of CETP (cholesteryl ester transfer protein) inhibitors has had a long and difficult course with 3 compounds failing in phase III clinical trials. Finally, the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification) trial has shown that the CETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy. Although the result is different to earlier studies, this is likely related to the size and duration of the trial. The benefit of anacetrapib seems to be largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C. Although the magnitude of benefit for coronary heart disease appeared to be moderate, in part this may have reflected aspects of the trial design. Anacetrapib treatment was associated with a small increase in blood pressure, but was devoid of major side effects and was also associated with a small reduction in diabetes mellitus. Treatment with CETP inhibitors, either alone or in combination with statins, could provide another option for patients with coronary disease who require further reduction in LDL (low-density lipoprotein) and non-HDL-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“inhibitor that raised HDL-C less and did not reduce LDL-C; furthermore, its trial dal-OUTCOMES was stopped early.(3) The”
BackgroundCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Self-citationHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Self-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862
Self-citationInazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Self-citationEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · cited 1×
“2 years for futility.(4) In contrast, REVEAL was continued through”
BackgroundSelf-citationSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Zhong, S., Sharp, D. S., Grove, J. S., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 583
Self-citationChen, W., Stambolian, D., Edwards, A. O., Branham, K. E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M. A., Campochiaro, P. A., Klein, M. L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912702107 · Cited by 506
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · cited 1×
“0-fold) when potent CETP inhibitors are used alone versus when they are added to statins.(49,50) In earlier trials (Table), the degree of LDL-C lowering by CETP inhibitors was overestimated likely reflecting changes in apoB particle composition(34)”
BackgroundWebb, T. R., Erdmann, J., Stirrups, K. E., Stitziel, N. O., Masca, N. G. D., Jansen, H., Kanoni, S., Nelson, C. P., Ferrario, P. G., König, I. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.056 · Cited by 252
Self-citationYvan-Charvet, L., Kling, J., Pagler, T., Li, H., Hubbard, B., Fisher, T., Sparrow, C. P., Taggart, A. K., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207142 · Cited by 240
Self-citationHovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B., & Barter, P. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60158-1 · Cited by 239
Self-citationBarter, P. J., Rye, K.-A., Tardif, J.-C., Waters, D. D., Boekholdt, S. M., Breazna, A., & Kastelein, J. J. P. (2011) · Circulation · doi:10.1161/circulationaha.111.018259 · Cited by 198
Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA
Jiang, X. C., Moulin, P., Quinet, E., Goldberg, I. J., Yacoub, L. K., Agellon, L. B., Compton, D., Schnitzer-Polokoff, R., & Tall, A. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)64369-1 · Cited by 187
Self-citationNew loci and coding variants confer risk for age-related macular degeneration in East Asians
Cheng, C.-Y., Yamashiro, K., Jia Chen, L., Ahn, J., Huang, L., Huang, L., Cheung, C. M. G., Miyake, M., Cackett, P. D., Yeo, I. Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7063 · Cited by 179
Ikewaki, K., Rader, D. J., Sakamoto, T., Nishiwaki, M., Wakimoto, N., Schaefer, J. R., Ishikawa, T., Fairwell, T., Zech, L. A., & Nakamura, H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116750 · Cited by 166
Self-citationGenetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156
Whitlock, M. E., Swenson, T. L., Ramakrishnan, R., Leonard, M., Marcel, Y. L., Milne, R. W., & Tall, A. R. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114132 · Cited by 126
Self-citationNicholls, S. J., Ruotolo, G., Brewer, H. B., Kane, J. P., Wang, M.-D., Krueger, K. A., Adelman, S. J., Nissen, S. E., & Rader, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.013 · Cited by 121
Self-citationJiang, X., Masucci-Magoulas, L., Mar, J., Lin, M., Walsh, A., Breslow, J. L., & Tall, A. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74263-x · Cited by 108
Self-citationDidichenko, S. A., Navdaev, A. V., Cukier, A. M. O., Gille, A., Schuetz, P., Spycher, M. O., Thérond, P., Chapman, M. J., Kontush, A., & Wright, S. D. (2016) · Circulation Research · doi:10.1161/circresaha.116.308685 · Cited by 106
Ikewaki, K., Nishiwaki, M., Sakamoto, T., Ishikawa, T., Fairwell, T., Zech, L. A., Nagano, M., Nakamura, H., Brewer, H. B., & Rader, D. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118196 · Cited by 100
Self-citationThomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96
Self-citationAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes‐Soffer, G., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 89
Self-citationNomura, A., Won, H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D. M., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 89
Self-citationKOIZUMI, J., Inazu, A., Yagi, K., Koizumi, I., Uno, Y., Kajinami, K., Miyamoto, S., Moulin, P., Tall, A. R., & Mabuchi, H. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90114-i · Cited by 88
Self-citationTorcetrapib impairs endothelial function in hypertension
Simic, B., Hermann, M., Shaw, S., Bigler, L., Stalder, U., Doerries, C., Besler, C., Lüscher, T. F., & Ruschitzka, F. T. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr348 · Cited by 86
Tardif, J., Rhainds, D., Brodeur, M. R., Zada, Y. F., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L’Allier, P. L., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001405 · Cited by 73
Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits
Zhang, J., Niimi, M., Yang, D., Liang, J., Xu, J., Kimura, T., Mathew, A. V., Guo, Y., Fan, Y., Zhu, T., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309114 · Cited by 69
Krishna, R., Gheyas, F., Liu, Y., Hagen, D., Walker, B., Chawla, A., Côté, J., Blaustein, R. O., & Gutstein, D. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.700 · Cited by 58
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56 · cited 1×
“This supposition is supported by studies performed in a subset of patients in the DEFINE (Determining the Efficacy and tolerability of CETP inhibition with anacetrapib) trial which showed a larger absolute reduction in LDL-C by anacetrapib in patients with higher LDL-C at baseline compared with those with lower levels…”
ResultTime to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 52
Genetic variants in CETP increase risk of intracerebral hemorrhage
Anderson, C. D., Falcone, G. J., Phuah, C., Radmanesh, F., Brouwers, H. B., Battey, T. W. K., Biffi, A., Peloso, G. M., Liu, D. J., Ayres, A. M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24780 · Cited by 40
Barter, P. J., Nicholls, S. J., Kastelein, J. J. P., & Rye, K.-A. (2015) · Circulation · doi:10.1161/circulationaha.114.014025 · Cited by 33
Cochran, B. J., Hou, L., Manavalan, A. P. C., Moore, B. M., Tabet, F., Sultana, A., Torres, L. C., Tang, S., Shrestha, S., Senanayake, P., et al. (2016) · Diabetes · doi:10.2337/db16-0668 · Cited by 30
Self-citationAssessing the mechanisms of cholesteryl ester transfer protein inhibitors
Zhang, M., Lei, D., Peng, B., Yang, M., Zhang, L., Charles, M. A., Rye, K., Krauss, R. M., Johns, D. G., & Ren, G. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.09.004 · Cited by 29
Ezetimibe plus a Statin after Acute Coronary Syndromes.
Cannon, C. P., Blazing, M. A., & Braunwald, E. (2015) · PubMed · doi:10.1056/nejmc1509363 · Cited by 26
Increasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Self-citationCETP Inhibitors — A New Inning?
Hegele, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711407 · Cited by 23
Millar, J. S., Lassman, M. E., Thomas, T. A., Ramakrishnan, R., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074880 · Cited by 22
Self-citationMessas, N., Dubé, M., & Tardif, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0679-5 · Cited by 8
High-Density Lipoproteins, Endothelial Function, and Mendelian Randomization
Westerterp, M., Wang, N., & Tall, A. R. (2016) · Circulation Research · doi:10.1161/circresaha.116.309116 · Cited by 6
Self-citation
Cited by
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572
Lipid transfer proteins: the lipid commute via shuttles, bridges and tubes
Wong, L. H., Gatta, A. T., & Levine, T. P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0071-5 · Cited by 505
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
Metadata
- Authors
- Tall, A. R., & Rader, D. J.
- Venue
- Circulation Research
- Published
- 2018-01-05
- Volume
- 122
- Issue
- 1
- Pages
- 106-112
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2764023940
- Cited by
- 305
- References
- 50
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.